** Shares of Telix Pharmaceuticals TLX.AX rise as much as 1.9% to A$17.35, hitting their highest level since September 23, 2025

** Stock marks its fourth consecutive session of gains

** The biopharmaceutical co and U.S. FDA align on advancement into Part 2 of the ProstACT Global Phase 3 study in U.S.

** Company says FDA confirmed Part 1 safety data supports starting U.S. Part 2 of ProstACT Global, testing two TLX591-Tx doses alongside standard therapies

** Initiation of Part 2 in the U.S. remains subject to the FDA's review of an Investigational New Drug amendment, Telix says

** "We do not think 591 is likely to come close to failing a futility analysis", Citi says, adding the event removes an overhang from shares in their view

** TLX stock up 53.9% YTD, including the session's moves